Posted originally on the conservative tree house on May 13, 2022 | Sundance
Fake News CNN’s Jake Tapper asks White House Chief Medical Advisor Anthony Fauci why the White House is sending out false information, aka ‘disinformation’, about when the COVID vaccines were available. Fauci giggles, laughs and says “I have no idea.” WATCH:
U.S. politics has devolved into a grand pretense of a theatrical performance keeping everyone distracted from the severe damage being inflicted by the political ideologues within the Biden administration.
I guarantee you if someone were just to ask Joe Biden at a presser who his Interior Secretary or EPA Administrator were, he’d have absolutely no idea. Biden is purposefully and completely isolated from the policies being carried out by the people running the administration. Biden has no idea what they are doing. None.
Clueless and disconnected Joe Biden is a shallow, empty and at times explosively angry vessel of nothingness. The entire world can see it.
The Australian government is spending millions on an ad campaign to encourage citizens to take a third COVID vaccine. Their method of marketing is quite surprising and I question who would be enticed to take the vaccine upon watching this ad. The campaign features individuals who received the two jabs — and still fell deathly ill with COVID.
You risked your life to take an experimental vaccine, twice, and STILL contracted the virus. Your symptoms were allegedly life-threatening, so the theory that the vaccine will lessen symptoms is moot here. All of that and people are still willingly taking the third vaccine. Cognitive dissonance is strong here.
Nearly 72% of Southern Australians are triple jabbed, yet the government feels it is worth spending $2 million to target that remaining portion who likely do not want another useless vaccine with known side effects. Governments across the globe were hoping we would all be mindless sheep, politely queuing each season for another immunization. Enough is enough.
By joelshirschhorn medical researcher, analyst at Joel S. Hirschhorn | Telling the truth with good data Published originally on TrialSite News on May. 12, 2022, 9:00 a.m.
A global medical mystery is being aggressively pursued by medical researchers. The core issue is that a relatively small fraction of people despite high exposure to COVID have not gotten ill with COVID infection. Think of health workers in hospitals in contact with many seriously ill COVID patients. Also, members of households that stood out because unlike others in the home who got ill with COVID they did not get infected. The mystery is what explains how highly exposed individuals did not get ill with COVID infection.
There are two main ways of explaining resistance to COVID. One is that some people have strengthened their immune systems by any of a number of actions taken before or during the pandemic. For example, some may have elevated levels of vitamin D in their blood by taking high doses of supplements. The other explanation that appeals to medical researchers is that some people have a genetic makeup that gives them total defense against COVID infection,
TrialSite Staff by Staff at TrialSite | Quality Journalism May. 10, 2022, 9:00 a.m.
After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.
In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response.
Vaccine producers such as Pfizer, Moderna, Johnson and Johnson (Janssen), AstraZeneca, and others understand that unless there are continued government mandates effectively priming the pump of demand, those individuals with a preference for COVID-19 immunization have already gone ahead with the procedure.
What’s left is a market for boosters and what could become some sort of annual shot available for targeted populations. Of course, in some markets, young children are still a target for COVID-19 vaccines. Regardless, companies now operate in a quite different environment now, than they did in the period of late 2020 through 2021: a period driven by massive government spending, heavy industry influence on the regulatory process, risk-sharing, and the like to a more traditional competitive marketplace.
The Last Market: Young Children
While the children’s markets in places like America are still relevant, awaiting approval, what’s becoming apparent will be the emphasis on booster shots. In the world’s most lucrative drug market, America, Pfizer, and Moderna will more than likely persist as market leaders vying for the parental demands of children as public health agencies such as the CDC continue to emphasize that the risk-benefit analysis of the COVID-19 vaccine favor by a long-shot vaccination. The point of view is that there are no risk-free choices and that it’s better to be safe than sorry with the very youngest members of society.
To date, the CDC recommends the Pfizer vaccine for both the 5-11 age and 12 to 17 cohort while not recommending Moderna. Under 4 is the last market segment the vaccine makers vie for, and if the FDA authorizes, then Pfizer would own that market. A potential battle emerges over this cohort (aged 4-11) as a growing movement concerned for the safety associated with the vaccines, especially the mRNA-based products, gains momentum to question the mass vaccination on this young population. Critics argue that the original premise for mandates and the like was to control community transmission. Given substantial waning vaccine effectiveness combined with mutating variants, critics suggest the risks of serious infection and death are too low, and the safety issues are higher than the government is letting on.
Demand for Vaccines Wane
But demand for vaccines is flat in much of the world. In America, there is little uptick in vaccination as the “fully vaccinated” defined as receiving the two jabs of either Pfizer-BioNTech, Moderna or one jab from Janssen equals 66.8% of the population while about 30.7% of the population opted for a booster dose.
Meanwhile, TrialSite, on several occasions, has chronicled a global glut of COVID-19 vaccines and therapeutics, especially in places like India, the world’s second-highest populated country. In places like Australia, where the death rate associated with COVID-19 has absolutely skyrocketed despite high immunization rates, the public health agencies and politicians continue to promote booster doses as the answer. TrialSite reported recently that Australian politicians in an election season essentially pretend that times are back to normal despite record numbers of cases, near-record hospitalizations, and double the deaths in the first months of 2022 than all of 2020 and 2021 combined.
Some Possible Explanations
Reuters’ Michael Erman and Manas Mishra write that vaccine producers such as Novavax and CureVac, the German mRNA-vaccine maker in partnership with GlaxoSmithKline, seek to target this booster market. Novavax still awaits FDA authorization despite the fact that much of the developed world, from Europe to Canada and Japan to the WHO, have authorized the use of the Novavax vaccine.
Meanwhile, the outlook for Janssen and AstraZeneca (Oxford) is that bright, report the Reuters journalists. According to Hartaj Singh, an analyst from Oppenheimer & Co., “It becomes a very competitive game with companies battling it out with pricing and for market share, even for vaccines that are considered to be the best, like Pfizer and Moderna.”
Interestingly, Pfizer’s CEO Albert Bourla went on the record in an interview recently that those adults that have opted to receive a COVID-19 vaccine are not likely to start accepting shots now in a recognition that the mega push for vaccine administration has come and gone.
Moderna has pegged the unfolding market as the annual shot market, targeting the following:
Adults 50 and above
People with comorbidities or other risks
High-risk occupations (e.g., healthcare, etc.)
According to the estimates of Stephane Bancel, Moderna’s CEO, this emerging annual shot market totals 1.7 billion, representing 21% of the global population. The mRNA-based vaccines are more expensive and cumbersome to distribute and store, hence a sizeable chunk of that estimated target may opt for other vaccines such as the two recently touted by vaccine insiders at WHO including a plant-based vaccine from Canada and one from China.
More than likely Western Europe and America will represent central markets for sales for Pfizer and Moderna who will move toward more competitive, targeted responsive strategies as large government pre-purchases are probably going to be far less. Moreover, TrialSite suggests what were cozy relationships between industry and government agencies will become less so as the various governments’ responses to the pandemic will be a hot topic, especially in democracies in current election cycles.
Key Question: A flu shot model or something else?
The Reuters writers posed an important question in the recent piece: will the likes of Pfizer and Moderna starting this fall market a tailored, redesigned vaccine targeted relevant variants of concern (e.g., Omicron, BA.2, etc.)?
Both Moderna and Pfizer executives are on the record that they are developing Omicron-targeted vaccines.
This becomes an important topic as even the mainstream media starts to become slightly critical of the pandemic response, including mRNA-based vaccine makers that never modified the vaccine product once. The vaccine authorized and approved in the United States was developed based on the original Wuhan variant of SARS-CoV-2 which didn’t seem to make it in circulation to America nor most of the world.
Revenues Decline (but still unprecedented)
2023 sales numbers, while still staggering as compared to historical precedent in the pharmaceutical industry, are nonetheless, on the decline. Reuters reports $17 billion projected for Pfizer-BioNTech (down nearly half from $34 billion) and $10 billion for Moderna as compared to $23 billion in 2022. Sales will continue to drop because enormous fortunes were generated in the winner-take-all pandemic market.
TrialSite suggests the COVID-19 pandemic response must be seriously evaluated due to levels of bias, political interference, and potentially corruption at an unprecedented level. Should the political conditions change in the United States for example, leading to serious inquiries, the pandemic winners may incur unexpected costs.
After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.
In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response. TrialSite Staff by Staff at TrialSite | Quality Journalism
May. 10, 2022, 9:00 a.m.
After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.
In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response.
Vaccine producers such as Pfizer, Moderna, Johnson and Johnson (Janssen), AstraZeneca, and others understand that unless there are continued government mandates effectively priming the pump of demand, those individuals with a preference for COVID-19 immunization have already gone ahead with the procedure.
What’s left is a market for boosters and what could become some sort of annual shot available for targeted populations. Of course, in some markets, young children are still a target for COVID-19 vaccines. Regardless, companies now operate in a quite different environment now, than they did in the period of late 2020 through 2021: a period driven by massive government spending, heavy industry influence on the regulatory process, risk-sharing, and the like to a more traditional competitive marketplace.
The Last Market: Young Children
While the children’s markets in places like America are still relevant, awaiting approval, what’s becoming apparent will be the emphasis on booster shots. In the world’s most lucrative drug market, America, Pfizer, and Moderna will more than likely persist as market leaders vying for the parental demands of children as public health agencies such as the CDC continue to emphasize that the risk-benefit analysis of the COVID-19 vaccine favor by a long-shot vaccination. The point of view is that there are no risk-free choices and that it’s better to be safe than sorry with the very youngest members of society.
To date, the CDC recommends the Pfizer vaccine for both the 5-11 age and 12 to 17 cohort while not recommending Moderna. Under 4 is the last market segment the vaccine makers vie for, and if the FDA authorizes, then Pfizer would own that market. A potential battle emerges over this cohort (aged 4-11) as a growing movement concerned for the safety associated with the vaccines, especially the mRNA-based products, gains momentum to question the mass vaccination on this young population. Critics argue that the original premise for mandates and the like was to control community transmission. Given substantial waning vaccine effectiveness combined with mutating variants, critics suggest the risks of serious infection and death are too low, and the safety issues are higher than the government is letting on.
Demand for Vaccines Wane
But demand for vaccines is flat in much of the world. In America, there is little uptick in vaccination as the “fully vaccinated” defined as receiving the two jabs of either Pfizer-BioNTech, Moderna or one jab from Janssen equals 66.8% of the population while about 30.7% of the population opted for a booster dose.
Meanwhile, TrialSite, on several occasions, has chronicled a global glut of COVID-19 vaccines and therapeutics, especially in places like India, the world’s second-highest populated country. In places like Australia, where the death rate associated with COVID-19 has absolutely skyrocketed despite high immunization rates, the public health agencies and politicians continue to promote booster doses as the answer. TrialSite reported recently that Australian politicians in an election season essentially pretend that times are back to normal despite record numbers of cases, near-record hospitalizations, and double the deaths in the first months of 2022 than all of 2020 and 2021 combined.
Some Possible Explanations
Reuters’ Michael Erman and Manas Mishra write that vaccine producers such as Novavax and CureVac, the German mRNA-vaccine maker in partnership with GlaxoSmithKline, seek to target this booster market. Novavax still awaits FDA authorization despite the fact that much of the developed world, from Europe to Canada and Japan to the WHO, have authorized the use of the Novavax vaccine.
Meanwhile, the outlook for Janssen and AstraZeneca (Oxford) is that bright, report the Reuters journalists. According to Hartaj Singh, an analyst from Oppenheimer & Co., “It becomes a very competitive game with companies battling it out with pricing and for market share, even for vaccines that are considered to be the best, like Pfizer and Moderna.”
Interestingly, Pfizer’s CEO Albert Bourla went on the record in an interview recently that those adults that have opted to receive a COVID-19 vaccine are not likely to start accepting shots now in a recognition that the mega push for vaccine administration has come and gone.
Moderna has pegged the unfolding market as the annual shot market, targeting the following:
Adults 50 and above
People with comorbidities or other risks
High-risk occupations (e.g., healthcare, etc.)
According to the estimates of Stephane Bancel, Moderna’s CEO, this emerging annual shot market totals 1.7 billion, representing 21% of the global population. The mRNA-based vaccines are more expensive and cumbersome to distribute and store, hence a sizeable chunk of that estimated target may opt for other vaccines such as the two recently touted by vaccine insiders at WHO including a plant-based vaccine from Canada and one from China.
More than likely Western Europe and America will represent central markets for sales for Pfizer and Moderna who will move toward more competitive, targeted responsive strategies as large government pre-purchases are probably going to be far less. Moreover, TrialSite suggests what were cozy relationships between industry and government agencies will become less so as the various governments’ responses to the pandemic will be a hot topic, especially in democracies in current election cycles.
Key Question: A flu shot model or something else?
The Reuters writers posed an important question in the recent piece: will the likes of Pfizer and Moderna starting this fall market a tailored, redesigned vaccine targeted relevant variants of concern (e.g., Omicron, BA.2, etc.)?
Both Moderna and Pfizer executives are on the record that they are developing Omicron-targeted vaccines.
This becomes an important topic as even the mainstream media starts to become slightly critical of the pandemic response, including mRNA-based vaccine makers that never modified the vaccine product once. The vaccine authorized and approved in the United States was developed based on the original Wuhan variant of SARS-CoV-2 which didn’t seem to make it in circulation to America nor most of the world.
Revenues Decline (but still unprecedented)
2023 sales numbers, while still staggering as compared to historical precedent in the pharmaceutical industry, are nonetheless, on the decline. Reuters reports $17 billion projected for Pfizer-BioNTech (down nearly half from $34 billion) and $10 billion for Moderna as compared to $23 billion in 2022. Sales will continue to drop because enormous fortunes were generated in the winner-take-all pandemic market.
TrialSite suggests the COVID-19 pandemic response must be seriously evaluated due to levels of bias, political interference, and potentially corruption at an unprecedented level. Should the political conditions change in the United States for example, leading to serious inquiries, the pandemic winners may incur unexpected costs.
After 16 months of major COVID-19 immunization initiatives worldwide, government appetite for COVID-19 vaccine products appears to morph into a more focused, market-based, targeted booster series, a change that vaccine producers are now adjusting to accommodate. With a confluence of forces, from COVID-19 vaccine gluts to increasing numbers of producers to leeriness of waning effectiveness due to highly transmissible variants, the market drivers, heavily driven by government, give way to an unfolding new reality.
In the United States, like in many other nations, including those aligned with the World Health Organization (WHO), centered responses to COVID-19 emphasized production and distribution of a maximum number of vaccines with targets of achieving at least 70% vaccination. That effort, again coordinated to some degree by groups such as WHO, led to the inoculation of about 4.68 billion people (according to Our World in Data) worldwide, or neatly 60% of humanity, representing an unprecedented pandemic response.
The FDA has finally admitted what we knew all along – the vaccine is not safe. The FDA said it is limiting the availability of Johnson & Johnson’s COVID-19 vaccine as it does indeed cause blood clots. The agency also noted that the vaccine presents a risk of thrombosis with thrombocytopenia syndrome.
The health agencies are still pushing the vaccines from Moderna and Pfizer. How are they any different? The US government has a long history of punishing Johnson & Johnson for their illegal activities, from asbestos-laced baby powder to cancerogenic sunscreen. Yet, all pharmaceutical manufacturers are exempt from penalty for the COVID-19 vaccine, citing a national emergency.
FDA’s vaccine chief Dr. Peter Marks said that the risk of death is still better than not getting the jab and said Johnson & Johnson’s version may be used as a last resort. Johnson & Johnson was hoping to rake in $3.5 billion this year from the vaccine alone. All of this comes down to money and control. The government and businesses forced mandates with complete disregard for public health. The talking heads gaslit the world for years into believing anyone who questioned the vaccine was a conspiracy theory lunatic, unfit for society.
They have known the truth all along. The Johnson & Johnson vaccine came into question in April 2021. Here is Fauci maintaining that the Johnson & Johnson vaccine was “safe and effective” despite knowing it could be deadly:
Biden has been lying to the public since he entered his political career decades ago. Yet, he allegedly received more votes than any US president in history. Trust no one.
Armstrong Economics Blog/Basic Concepts Re-Posted May 6, 2022 by Martin Armstrong
QUESTION: Been following Martin since 2008 (Gold ride) – he is the only one who has been right AU and AG top 2011. ****Important question for Martin, please How can the fed raise rates with governments owing so much debt please ???? what are the consequences of debt restructured? 100 year treasury real estate Thanks you so much for sharing all your insights
JT
ANSWER: The Federal Reserve is independent. Despite all the nonsense that these pretend analysts attribute everything to the actions of the Fed, if they really knew their history, they would realize that the Fed has often been at war with the White House. You cannot be an objective analyst when you predetermine a conclusion based upon a theory you choose to believe. This is the sad state of analysis these days. People start with the conclusion and then cherry-pick the facts to support what they think should be the outcome. This is what has plagued gold analysis, but the very same process has doomed climate change analysis and the destruction of the world economy.
Unfortunately, when it comes to the Quantity Theory of Money, these analysts take the position of politicians and exonerate themselves of all responsibility for their reckless fiscal spending. They endlessly try to bribe the people to vote for them. I have stated many times, pre-1971, when it was illegal to borrow against an E-Bond, for example, the theory was printing money increased the supply and was inflationary. Thus, borrowing did not increase the money supply and was not inflationary. But when you can post T-Bills as collateral and trade the markets, that theory is no longer valid, so debt is now simply money that pays interest the way it began in 1861. We seem to always return to the starting place, like the game of Monopoly where you must pass Go every trip around the board.
Socialism is the worst form of government; just look at the Democrats. They do not know how to run for office without promising free something or other. It is never about the fate of the world, the nation, or our families. They are promoting war because they assume that the people will not change the government in the middle of a war. They have no problem watching our people die.
The Fed has ZERO control over fiscal spending. Nevertheless, the Fed has been itself brainwashed, and because everyone blames them for inflation, they will be compelled to raise rates or suffer the calls for their overthrow. The increased cost in the deficit will never be blamed on them — only the inflation rate. This is why the central banks have ZERO control over the economy anymore. Soon, people will wake up and realize that this statement is true. When they do, we will get a 1987-style panic.
Here is a chart of the dollar index. The dollar had already begun its decline when they stood up at the Plaza Accord, announcing they wanted the dollar down by 40%. As the dollar began to fall rapidly, other member nations complained. In February 1987, they gathered together to announce that the dollar had fallen too far and enough was enough. When the dollar continued lower, the then G7 lost all credibility, and the markets suddenly realized they were not in control.
This is what we will see once again. This type of inflation was caused by the COVID lockdowns. China may really have shut down Shanghai to push inflation even higher in the West, seeking regime change in Washington, hoping the inflation will lead to a political blood-bath for the Democrats to get the world back to some normalcy. When inflation is set in motion because of a shortage, like crop failures, raising interest rates will not suddenly make it rain.
The Fed will act out its role because it has no other choice. Its rate hike this week is only playing catch-up with the market. Rates are rising because they are supposed to reflect the inflation rates plus a profit. That’s without the Fed trying to manage the economy. Just look at the rates and ignore the pundits. You will see that the Fed is chasing the market, it is not driving the market. Hence, the Fed is being compelled to raise rates not by its own desire to prevent inflation, but to keep pace with the markets themselves.
The idiots will blame the Fed as inflation rises and blame them for not acting. There is no saving grace for the Fed. The system is collapsing and this is in fact what gives Klaus Schwab power, for they know in Europe that they can no longer borrow money to fund socialism. The answer is to default on all debt and to hide that, they need to make it sound like they are doing this for you — who they care so much about.
Hence, this default will be disguised as relieving you of all your debt when it is the governments who are defaulting, and unable to raise interest rates in Europe. This is also the backdrop to the Repo Crisis and why US banks withdrew from making markets because they did not want to take European debt as collateral, forcing the Federal Reserve to step in.
Pelosi’s delegation went to Ukraine and said the US does not want peace and it will not accept the status quo. They want total victory against Russia and they have UNCONSTITUTIONALLY declared war on Russia and they are pretending they can act unilaterally and as long as the Ukrainian people are on the ground and not American troops, then it is not formally a war that only the people can declare under the constitution. This is all a cover for the Great Default because Keynesian Economics has completely failed. The central banks CAN NOT stop this inflation nor do they control the fiscal spending. Governments are now spending whatever they want because they know the Great Default is coming. This is all part of the Great Reset pushed as the solution by the World Economic Forum.
As we move head-first into 2032, we are looking at the total collapse of not just socialism because of the inability of European governments to continue to borrow as the Fed raises rates, and they cannot, but we are also staring into the eyes of the collapse of Republican forms of government on a global scale.
Posted originally on the conservative tree house on May 5, 2022 | Sundance
You might remember that ancient time in history when American civics discussions involved the separation of powers. Apparently, those days are long gone in the rubble of what was once considered a constitutional republic. Forget Joe Biden targeting the President of Russia for assassination, what happened today is far more serious in context.
The most powerful political office in the executive branch of government, the office of The President, is now endorsing the political, potentially violent, targeting of the justices within the most powerful office of the judicial branch of power, the justices of The Supreme Court of the United States.
Pause for a moment and let that settle in.
The President is now endorsing the targeting of Supreme Court justices. The Executive Branch is now publicly targeting the Judicial Branch.
Separate but co-equal? Again, think about the ramifications here. WATCH:
Posted originally on the conservative tree house on May 5, 2022 | Sundance
The FDA has limited the use of the Johnson and Johnson COVID vaccine to only those over 18-years-old due to blood clotting issues. [Press Release Here] Johnson & Johnson’s Covid-19 vaccine is now limited to adults due to the risk of a rare blood clotting syndrome.
FDA – “Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.” (read more)
WHAT CHANGED? – “The FDA and CDC have continuously monitored for and investigated all suspected cases of TTS reported to VAERS. In an updated analysis of TTS cases following administration of the Janssen COVID-19 Vaccine that were reported to VAERS through March 18, 2022, the FDA and CDC have identified 60 confirmed cases, including nine fatal cases. The FDA has determined that the reporting rate of TTS is 3.23 per million doses of vaccine administered and the reporting rate of TTS deaths is 0.48 per million doses of vaccine administered.”
Posted originally on the conservatives tree house onMay 5, 2022 | Sundance
The White House has announced {SEE HERE} that Karine Jean-Pierre will replace Jen Psaki as chief narrative engineer for the Biden regime effective May 13, 2022. Anita Dunn will return as media fixer.
[White House Press Release] – Today, President Biden announced Karine Jean-Pierre has been promoted to be Assistant to the President and White House Press Secretary. Karine will step into the Press Secretary role replacing Jen Psaki, who will depart from the White House on May 13.
Statement from President Biden: “I am proud to announce that Karine Jean-Pierre will serve as the next White House Press Secretary.
“Karine not only brings the experience, talent and integrity needed for this difficult job, but she will continue to lead the way in communicating about the work of the Biden-Harris Administration on behalf of the American people. Jill and I have known and respected Karine a long time and she will be a strong voice speaking for me and this Administration. (read more)
Additionally, the White House has announced Anita Dunn will return to the JoeBama administration as senior advisor. Dunn’s specific expertise is using pressure, blackmail and political leverage to control information distribution by media organizations.
The reappearance of Anita Dunn aligns with the expressed intent of the DHS ‘disinformation’ board. Dunn’s professional political skillset surrounds being a paid media fixer. She has done this for multiple democrat politicians including Obama. It was Anita Dunn who used her position in the Biden campaign to demand that media stop allowing Rudy Guiliani to explain the Biden family ‘pay to play’ financial system of selling influence.
Anita Dunn also advised Harvey Weinstein how to remove media stories of his Hollywood rape issues.
Dunn reappearing makes sense, as the U.S. government objective to control information is now in full swing.
I have created this site to help people have fun in the kitchen. I write about enjoying life both in and out of my kitchen. Life is short! Make the most of it and enjoy!
This is a library of News Events not reported by the Main Stream Media documenting & connecting the dots on How the Obama Marxist Liberal agenda is destroying America
Centinel2012 